Sunitinib Malate

FDA Approved: * January 30, 2014
Pharm Company: * MYLAN PHARMS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Sunitinib Malate Overview

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.[1] Contents 1 Mechanism of action 2 Indications 2.1 Gastrointestinal...

Read more Sunitinib Malate Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sunitinib

Recent Sunitinib Malate Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sunitinib Malate

Capsule: 12.5mg, 25mg, 37.5mg, 50mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Sunitinib Malate or a similar ingredient: (1 result)

SUTENT Sunitinib Malate10 discussions